mCRPC VL

Exploring the New Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans

Details
In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...

Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor

Details
Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...

A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore

Details
Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...

ODM-208: A New Hope for Treatment-Resistant Prostate Cancer - Karim Fizazi

Details
Alicia Morgans interviews Karim Fizazi to discuss his presentation on the CYPIDES Phase I-II trial. The trial focuses on ODM-208, a CYP11 inhibitor developed with Orion, aimed at treating men with advanced prostate cancer who have exhausted conventional therapies and exhibit androgen receptor mutations. Dr. Fizazi explains that the compound targets the precursor enzymes for various steroids, there...

A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate Cancer Setting - Neal Shore

Details
Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...

Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...

Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke

Details
At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for All...

Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022 Presentation - Anwar Padhani

Details
During the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), Anwar Padhani presents risk-adapted treatment monitoring in mCRPC (which imaging methods, when and how often). Biographies: Anwar Padhani, MBBS, FRCP, FRCR, Consultant, Radiologist & Professor, Cancer Imaging, Paul Strickla...

Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Neal Shore presents the role of radium-223 in the modern treatment armamentarium in metastatic castration-resistant prostate cancer (mCRPC) patients. Biographies: Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, Sout...

How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi

Details
Kim Chi presents an overview of how to read a genomics testing report during APCCC 2022. His presentation includes a discussion of prostate cancer-relevant genes, reading the FoundationOne CDx test, and more. Chi explains the importance of understanding the intricacies of the genomics report and its limitations given that tumor genomics is now a standard part of the workup for patients with advanc...